Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Eur J Cardiothorac Surg ; 41(6): 1377-83, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22219475

ABSTRACT

OBJECTIVES: Levosimendan is a novel inotropic agent claimed to improve myocardial contractility by a calcium-sensitizing effect. Our aim was to evaluate dose-dependent effects of levosimendan on left ventricular (LV) contractility and energetic properties in an acute, ischaemic heart failure porcine model. METHODS: Six pigs were used in an anaesthetized in vivo open-chest model. The time points of measurements were: baseline, after heart failure induction and after dose 1-4 (D1-D4). Heart failure was induced by microembolization of the left coronary artery before infusion of four different doses (D1: 2.5 µg/kg, D2: 10 µg/kg, D3: 40 µg/kg, D4: 80 µg/kg) of levosimendan. Haemodynamics were assessed by the pressure-conductance catheter technique. LV oxygen consumption was calculated from coronary flow measurements and coronary sinus blood gases. Mitochondrial respiration was studied in biopsies of the LV. RESULTS: Levosimendan had no significant, load-independent effect on contractile force (slope of preload recruitable stroke work was 34 mmHg immediately following failure and 39 (P = 0.406), 42 (P = 0.219), 46 (P = 0.067) and 41 (P = 0.267) at D1-D4), although the more load-dependent contractility indicator of dP/dt(max) was slightly increased at dose 4 (P < 0.05). LV energy conversion efficiency (PVA-MVO2 relationship) remained unaltered at all doses. Maximal mitochondrial respiration decreased after induction of failure and remained at an unaltered low level during levosimendan infusion. CONCLUSIONS: Surprisingly, levosimendan had no significant effect on contractility, energy efficiency and mitochondrial respiration of the LV, in a porcine model of acute heart failure. At high doses, levosimendan induced vasodilatation and increased heart rate and cardiac output.


Subject(s)
Cardiotonic Agents/administration & dosage , Heart Failure/physiopathology , Hydrazones/administration & dosage , Pyridazines/administration & dosage , Animals , Cardiotonic Agents/pharmacology , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Heart Failure/etiology , Hemodynamics/drug effects , Hemodynamics/physiology , Hydrazones/pharmacology , Mitochondria, Heart/drug effects , Mitochondria, Heart/physiology , Myocardial Contraction/drug effects , Myocardial Contraction/physiology , Oxygen Consumption/drug effects , Oxygen Consumption/physiology , Pyridazines/pharmacology , Simendan , Sus scrofa , Ventricular Function, Left/drug effects , Ventricular Function, Left/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...